Gut bacteria vaccine takes on colorectal cancer remnants
NCT ID NCT05350501
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 28 times
Summary
This study tested a new vaccine (EO2040) made from gut bacteria, combined with the immunotherapy drug nivolumab, in people with colorectal cancer who had tiny amounts of cancer DNA left in their blood after standard treatment. The goal was to see if the combination could clear these cancer remnants and prevent the cancer from coming back. The trial was terminated early after enrolling only one participant, so no conclusions can be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
MD Anderson
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.